Anavex Life Sciences has announced positive results from its 48-week Phase 2 extension study of
ANAVEX®2-73 (blarcamesine) in patients with Parkinson’s disease dementia. This
clinical-stage biopharmaceutical company has focused on developing treatments
for neurodegenerative and neurodevelopmental disorders, marking a significant
milestone in Parkinson’s disease research. 

The study, identified as ANAVEX2-73-PDD-EP-001, achieved both primary and secondary
objectives, highlighting the efficacy of ANAVEX®2-73 in improving clinical
symptoms over the 48-week period. Notably, participants showed consistent
improvement in the Movement Disorder Society-Unified Parkinson’s Disease Rating
Scale (MDS-UPDRS), Clinical Global Impression – Improvement (CGI-I), and
cognitive function measured by the Montreal Cognitive Assessment (MoCA). 

Christopher U Missling, PhD, President and CEO of Anavex, stated, “It is encouraging that the
patients’ clinical symptoms consistently improved longitudinally over time
during the extension phase under active ANAVEX®2-73 treatment.” This
underscores the potential of ANAVEX®2-73 to address the urgent unmet needs in
Parkinson’s disease management. 

Participants were allowed to continue their stable regimen of existing Parkinson’s medications,
enhancing the study’s real-world applicability. Despite the COVID-19-induced
delay, which led to a ‘drug holiday,’ the extension phase results were
promising. The resumption of ANAVEX®2-73 treatment saw a reversal of symptom
worsening experienced during the drug holiday. 

Anavex Life Sciences plans to proceed with a pivotal 6-month study based on these findings.
The company’s lead drug candidate, ANAVEX®2-73, continues to show potential beyond Parkinson’s disease, with ongoing
studies in Alzheimer’s disease and Rett syndrome. 

Funded by a grant from The Michael J. Fox Foundation, these results could pave the way for future
advancements in Parkinson’s disease therapeutics. Anavex Life Sciences remains
at the forefront of neurodegenerative research, committed to delivering novel
and effective treatments. Follow this page on Instagram, for related information. 

Learn more about Anavex on https://www.bloomberg.com/profile/company/AVXL:US